Deal will let more companies make an overdose antidote spray

A deal between Emergent BioSolutions and the attorney general's office of New York could allow more companies to offer a nasal spray formulation of the overdose antidote drug nalmefene. Emergent enjoyed exclusive rights to develop and market the drug, which is still in the pipeline, but it has agreed not to exercise those rights.

A deal between Emergent BioSolutions and the attorney general's office of New York could allow more companies to offer a nasal spray formulation of the overdose antidote drug nalmefene. Emergent enjoyed exclusive rights to develop and market the drug, which is still in the pipeline, but it has agreed not to exercise those rights. Companies that pursue development of similar products, meanwhile, will be subject to the customary regulatory scrutiny. Emergent also sells Narcan—a spray version of naloxone, another opioid reversal agent—but it is not covered by an exclusivity agreement.